News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,650 Results
Type
Article (14064)
Company Profile (282)
Press Release (249304)
Section
Business (79435)
Career Advice (152)
Deals (13215)
Drug Delivery (34)
Drug Development (50382)
Employer Resources (31)
FDA (5699)
Job Trends (5121)
News (144255)
Policy (10023)
Tag
Academia (901)
Alliances (21592)
Alzheimer's disease (784)
Antibody-drug conjugate (ADC) (70)
Approvals (5687)
Artificial intelligence (90)
Bankruptcy (100)
Best Places to Work (4554)
Biotechnology (232)
Breast cancer (124)
Cancer (1051)
Cardiovascular disease (85)
Career advice (132)
CAR-T (86)
Cell therapy (250)
Clinical research (40448)
Collaboration (409)
Compensation (166)
COVID-19 (1020)
C-suite (105)
Cystic fibrosis (73)
Data (1076)
Diabetes (100)
Diagnostics (1248)
Drug discovery (65)
Earnings (29094)
Events (47526)
Executive appointments (332)
FDA (6156)
Funding (389)
Gene editing (73)
Gene therapy (189)
GLP-1 (336)
Government (1071)
Healthcare (6562)
Infectious disease (1066)
Inflammatory bowel disease (100)
IPO (7236)
Job creations (859)
Job search strategy (127)
Layoffs (194)
Legal (1381)
Lung cancer (156)
Manufacturing (97)
Medical device (2569)
Medtech (2570)
Mergers & acquisitions (6190)
Metabolic disorders (302)
Neuroscience (1085)
NextGen: Class of 2025 (2013)
Non-profit (852)
Northern California (1254)
Obesity (163)
Opinion (95)
Parkinson's disease (88)
Patents (73)
People (25291)
Phase I (14281)
Phase II (18815)
Phase III (11888)
Pipeline (470)
Postmarket research (852)
Preclinical (5986)
Radiopharmaceuticals (208)
Rare diseases (236)
Real estate (1411)
Regulatory (8386)
Research institute (932)
Series A (75)
Southern California (1130)
Startups (1968)
United States (9993)
Vaccines (184)
Weight loss (94)
Date
Today (73)
Last 7 days (385)
Last 30 days (1690)
Last 365 days (20438)
2025 (1822)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27806)
2020 (23358)
2019 (16224)
2018 (11739)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Asia (17048)
Australia (2884)
California (2873)
Canada (913)
China (255)
Colorado (110)
Connecticut (119)
Europe (36679)
Florida (328)
Georgia (86)
Illinois (182)
Indiana (69)
Maryland (377)
Massachusetts (2287)
Minnesota (114)
New Jersey (716)
New York (793)
North Carolina (455)
Northern California (1254)
Ohio (93)
Pennsylvania (545)
South America (207)
Southern California (1130)
Texas (321)
Washington State (274)
263,650 Results for "3dbio therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
3DBio Therapeutics and the Microtia-Congenital Ear Deformity Institute Conduct Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial
3DBio Therapeutics, a clinical-stage regenerative medicine company, and the Microtia-Congenital Ear Deformity Institute announced they have conducted a human ear reconstruction using the AuriNovo™ implant, an investigational, patient-matched, 3D-bioprinted living tissue ear implant.
June 2, 2022
·
8 min read
Business
3DBio Therapeutics, Inc. Strengthens Board of Directors, Welcomes Scott Dylla, Ph.D.
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced Scott Dylla, Ph.D has joined its Board of Directors.
October 30, 2020
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Pharm Country
3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced it has received Orphan Drug Designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia
November 19, 2019
·
2 min read
Pharm Country
3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia.
December 6, 2019
·
3 min read
Press Releases
Allogene Therapeutics Announces Participation in February Investor Conferences
February 4, 2025
·
2 min read
Press Releases
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 30, 2025
·
4 min read
Press Releases
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
February 4, 2025
·
4 min read
Press Releases
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
January 30, 2025
·
1 min read
Press Releases
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
February 5, 2025
·
5 min read
1 of 26,365
Next
